Stock Traders Purchase High Volume of Call Options on Alector (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) saw unusually large options trading activity on Wednesday. Investors purchased 3,578 call options on the stock. This is an increase of approximately 790% compared to the typical daily volume of 402 call options.

Insider Buying and Selling

In other Alector news, insider Sara Kenkare-Mitra sold 41,687 shares of Alector stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total value of $46,689.44. Following the transaction, the insider owned 501,652 shares in the company, valued at approximately $561,850.24. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Neil Lindsay Berkley sold 37,261 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total value of $41,732.32. Following the completion of the transaction, the chief financial officer directly owned 374,309 shares in the company, valued at $419,226.08. This represents a 9.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 200,183 shares of company stock worth $230,262 in the last ninety days. 9.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its stake in Alector by 4.7% in the first quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock valued at $316,000 after buying an additional 11,618 shares in the last quarter. Strs Ohio bought a new stake in shares of Alector during the 1st quarter valued at approximately $126,000. Bank of Montreal Can bought a new stake in shares of Alector during the 2nd quarter valued at approximately $73,000. Los Angeles Capital Management LLC increased its position in Alector by 5.3% during the 2nd quarter. Los Angeles Capital Management LLC now owns 151,896 shares of the company’s stock worth $213,000 after purchasing an additional 7,600 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its stake in Alector by 50.7% in the 2nd quarter. Acadian Asset Management LLC now owns 2,170,388 shares of the company’s stock valued at $3,033,000 after purchasing an additional 729,727 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Alector Stock Performance

NASDAQ:ALEC opened at $2.56 on Friday. The firm has a market capitalization of $279.42 million, a PE ratio of -1.84 and a beta of 0.64. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.17. Alector has a 12-month low of $0.87 and a 12-month high of $3.40. The firm has a 50-day moving average price of $1.83 and a 200 day moving average price of $2.03.

Alector (NASDAQ:ALEC) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.05. The firm had revenue of $6.24 million for the quarter, compared to analyst estimates of $1.78 million. Alector had a negative net margin of 679.16% and a negative return on equity of 191.85%. Research analysts anticipate that Alector will post -1.88 earnings per share for the current fiscal year.

Key Alector News

Here are the key news stories impacting Alector this week:

• Positive Sentiment: Q4 results beat expectations — Alector reported GAAP EPS of ($0.34) vs. the consensus of ($0.39) and revenue of $6.24M vs. $1.78M expected; the revenue outperformance is the primary catalyst for the move higher. Company Press Release
• Positive Sentiment: Unusually large call buying — Traders bought ~3,578 call options (about +790% vs. typical daily volume), signaling short-term bullish positioning by options market participants. (Market options activity reported 2/25/26)
• Neutral Sentiment: Coverage & earnings write-ups — Multiple outlets posted earnings snapshots and the company business update summarizing the quarter; these provide context but largely reiterate the beats above. Business Insider: Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SFGate: Alector Q4 Earnings Snapshot
• Neutral Sentiment: Short-interest data appears inconsistent — Reports show “0 shares” and NaN changes for February, implying a likely data/reporting issue rather than a meaningful shift in short positioning; treat this as noisy/unreliable information for now.
• Negative Sentiment: Insider sale — Director Grace Wong‑Sarad sold 4,079 shares at an average $2.50 (SEC filing disclosed). While the sale is relatively small versus total float and insiders still hold stock, investors sometimes view insider selling as a cautionary signal. SEC Filing: Insider Sale

Analysts Set New Price Targets

A number of research firms have recently issued reports on ALEC. Wall Street Zen upgraded Alector from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Alector in a research report on Wednesday, January 21st. BTIG Research raised Alector from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Finally, Morgan Stanley restated an “underweight” rating on shares of Alector in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alector presently has an average rating of “Hold” and an average price target of $3.25.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.